Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.943
Neutral
RSI(14)
63.973
Neutral
STOCH(KDJ)(9,3,3)
66.599
Buy
ATR(14)
2.285
High Vlolatility
CCI(14)
18.353
Neutral
Williams %R
46.401
Neutral
TRIX(12,20)
0.231
Sell
StochRSI(14)
0.000
Sell
Johnson & Johnson
JNJ177.000USD
-1.130-0.63%
Market hours （ET）Quotes delayed by 15 min
426.00BMarket Cap
18.80P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-08Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
27
analysts
Buy
Current Rating
178.903
Target Price
+0.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 84.05%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.05%.
Fairly Valued
The company’s latest is 18.92, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.78B shares, decreasing 0.43% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 236.03M shares of this stock.
Financial Health
Currency: USD Updated：2025-09-08The company's current financial score is 7.74, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 21.89B, representing a year-over-year increase of 2.39%, while its net profit experienced a year-over-year increase of 237.91%.
Score
Financials
8.62
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.02
Operational Efficiency
7.38
Growth Potential
7.89
Shareholder Returns
7.79
Company Valuation
Currency: USD Updated：2025-09-08The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 18.78, which is 33.00% below the recent high of 24.97 and 38.13% above the recent low of 11.62.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 13/686
No Data
Earnings Forecast
Currency: USD Updated：2025-09-08The company’s current earnings forecast score is 7.12, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Johnson & Johnson is 176.00, with a high of 200.00 and a low of 155.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
27
analysts
Buy
Current Rating
178.903
Target Price
+0.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
179
Total
5
Median
8
Average
Company name
Ratings
Analysts
Johnson & Johnson
JNJ
27
Biogen Inc
BIIB
36
Amgen Inc
AMGN
34
Vertex Pharmaceuticals Inc
VRTX
33
Alnylam Pharmaceuticals Inc
ALNY
33
Eli Lilly and Co
LLY
31
1
2
3
...
36
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-08The company’s current price momentum score is 9.22, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 183.89 and the support level at 166.96, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
178.276
Sell
MA10
177.569
Sell
MA20
176.959
Buy
MA50
168.547
Buy
MA100
161.243
Buy
MA200
157.601
Buy
Institutional Confidence
Currency: USD Updated：2025-09-08The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 73.89%, representing a quarter-over-quarter decrease of 0.98%. The largest institutional shareholder is The Vanguard, holding a total of 236.03M shares, representing 9.80% of shares outstanding, with 1.79% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
State Street Global Advisors (US)
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
JP Morgan Asset Management
State Farm Insurance Companies
Norges Bank Investment Management (NBIM)
Morgan Stanley Smith Barney LLC
Wellington Management Company, LLP
BlackRock Asset Management Ireland Limited
1
2
Risk Assessment
Currency: USD Updated：2025-09-08The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 6.39, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.39
VaR
+1.58%
240-Day Maximum Drawdown
+14.35%
240-Day Volatility
+20.00%
Return
Best Daily Return
60 days
+6.19%
120 days
+6.19%
5 years
+6.19%
Worst Daily Return
60 days
-1.83%
120 days
-7.59%
5 years
-7.59%
Sharpe Ratio
60 days
+3.22
120 days
+0.96
5 years
+0.49
Risk Assessment
Maximum Drawdown
240 days
+14.35%
3 years
+21.19%
5 years
+23.63%
Return-to-Drawdown Ratio
240 days
+0.58
3 years
+0.13
5 years
+0.20
Skewness
240 days
-0.56
3 years
-0.03
5 years
+0.05
Volatility
Realised Volatility
240 days
+20.00%
5 years
+17.85%
Standardised True Range
240 days
+1.47%
5 years
+1.40%
Downside Risk-Adjusted Return
120 days
+109.56%
240 days
+109.56%
Maximum Daily Upside Volatility
60 days
+17.07%
Maximum Daily Downside Volatility
60 days
+11.65%
Liquidity
Average Turnover Rate
60 days
+0.35%
120 days
+0.37%
5 years
--
Turnover Deviation
20 days
+7.54%
60 days
+7.26%
120 days
+14.42%
Peer Comparison
Currency: USD Updated：2025-09-08Johnson & Johnson
JNJ
7.20 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BridgeBio Pharma Inc
BBIO
7.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Theravance Biopharma Inc
TBPH
7.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
